Trade Mark Journal No.2025/049 5 December 2025

UK00004300377 25 November 2025 (5)

AUDRANZOR

International priority date claimed: 7 November 2025 (United States of America) (99485064)

Class 5: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia,Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases anddisorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervoussystem diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia,dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders,fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammationand inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders,liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines,multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, obstructivesleep apnea, osteoarthritis, pain, Parkinson's disease, peripheral arterial disease, Psoriasis, Psoriaticarthritis, rheumatoid arthritis, ulcerative colitis, and vascular diseases; Pharmaceutical preparations.

Eli Lilly and Company

Representative: Page, White & Farrer Limited